Ultragenyx Pharmaceutical In holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 4,163,561 | $150,762,544 | 0.51% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 3,943,485 | $143,385,115 | 0.41% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2025 |
| Sept. 30, 2025 | 3,769,853 | $113,397,178 | 0.31% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 13, 2025 |
| Dec. 31, 2025 | 3,485,724 | $80,171,652 | 0.24% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 13, 2026 |
| March 31, 2026 | 3,214,533 | $67,344,466 | 0.26% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 8, 2026 |
| June 30, 2026 | 3,158,368 | $105,457,908 | 0.39% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.